Stockreport

MBX Biosciences Calls 2026 “Pivotal” With Phase 3 Plans, Obesity Program, and $460M Cash Runway [Yahoo! Finance]

MBX Biosciences, Inc.  (MBX) 
PDF is expected this quarter, one-year phase II OLE data in Q2, and a planned global registrational phase III start in Q3 alongside commercialization planning. The proprie [Read more]